SPD | Shifting Gears: Can Disease Course Be Changed in Patients With Pediatric Atopic Dermatitis?

Join experts Drs. Amy Paller and Peter Lio at an educational symposium as they investigate atopic dermatitis as a risk factor for the development of food allergies. The speakers will also discuss the benefits of early intervention in pediatric atopic dermatitis and the potential for disease modification.

MD, MS

Amy Paller +1 more

See post-event materials

Past event

13July2024

Location

Sheraton Centre Toronto

123 Queen St W ON M5H 2M9 Toronto Canada

Symposium Details

July 13

SPD | Shifting Gears: Can Disease Course Be Changed in Patients With Pediatric Atopic Dermatitis?

See On-Demand materials

Learning objectives

Discover how atopic dermatitis can be a risk factor for the development of food allergies
Describe the impact of potential opportunities for early intervention on disease trajectories
Understand the potential for disease modification in atopic dermatitis

Description

Uncover how atopic dermatitis can be a risk factor for the development of food allergies, the benefits of early intervention in pediatric atopic dermatitis, and the potential for disease modification with experts Drs. Amy Paller and Peter Lio.

Location

Sheraton Centre Toronto

123 Queen St W ON M5H 2M9 Toronto Canada

Speakers

Dermatology

MD, MS

Amy Paller

Walter J. Hamlin Professor and Chair of Dermatology; Professor of Pediatrics at Northwestern University, Evanston, Illinois, US

Dermatology

Peter Lio

Clinical Professor of Dermatology at the Icahn School of Medicine at Mount Sinai, NY; Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine, Chicago, Illinois, US

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ThailandChange country/region